Piper Sandler maintains Axsome Therapeutics stock rating with $148 target
PositiveFinancial Markets

Piper Sandler has reaffirmed its positive outlook on Axsome Therapeutics, maintaining a stock rating with a target price of $148. This endorsement highlights the firm's confidence in Axsome's potential for growth and innovation in the pharmaceutical sector, which could attract investors and boost market interest.
— Curated by the World Pulse Now AI Editorial System